Alterations in Gastrointestinal (GI) Motility and Related Disorders: Diarrhea, Constipation, and Irritable Bowel Syndrome (IBS)

Alterations in GI Motility and Related Disorders

Introduction

Alterations in gastrointestinal (GI) motility can lead to a range of clinical disorders, including diarrhea, constipation, and irritable bowel syndrome (IBS). Understanding the pathophysiology, clinical presentation, and treatment of these conditions is essential for effective diagnosis and management.

Diarrhea

Definition and Mechanisms

Diarrhea is defined as the excessive or frequent passage of loose or unformed stools. It is a result of altered intestinal fluid transport and secretion.

• Normal Intestinal Secretions: Approximately 7 liters/day; all but 100 mL are reabsorbed.

• Small bowel origin: Large volume loss.

• Colonic origin: Small volume loss.

• Intestinal fluid transport: Facilitated by Na+ transport (with Cl- or in exchange with H+) and paracellular pathways.

Classification

• Acute Diarrhea: Duration < 2 weeks; commonly infectious, drug-induced, or due to food intolerance.

• Chronic Diarrhea: Duration > 4 weeks; less commonly infectious, often due to intestinal disease.

Types of Acute Diarrhea

• Noninflammatory: Large volume, watery stools; absence of blood; typically caused by viruses or toxins (e.g., norovirus, rotavirus).

• Inflammatory: Small volume, bloody diarrhea; associated with fever and abdominal pain; commonly caused by bacterial pathogens (e.g., Salmonella, Shigella).

Types of Chronic Diarrhea

• Osmotic: GI lumen contains non-absorbable solutes; causes include lactose intolerance, malabsorption syndromes.

• Secretory: Excessive secretion into GI tract; causes include infections, certain tumors.

• Inflammatory conditions: Ulcerative colitis, Crohn's disease.

• GI motility disorders: Altered transit time, irritable bowel syndrome.

Manifestations

• Fluid loss: Dehydration, hypotension.

• Electrolyte loss: Hypokalemia, metabolic acidosis.

• Malnutrition

Treatment (General Approach)

• Remove reversible cause/condition if possible.

• Rehydration.

• Electrolyte replacement.

• Antibiotics for bacterial infection.

• Antimotility agents: Loperamide, diphenoxylate.

• Adsorbents: Kaolin-pectin.

• Antisecretory agents: Bismuth subsalicylate.

Constipation

Definition and Clinical Features

Constipation is characterized by infrequent bowel movements (≤ 3/week), hard, dry, small stools, straining during defecation, and a feeling of incomplete evacuation. There is significant interpatient variability in perception.

Pathophysiology

Primary Causes

• Normal transit (most common): Normal GI motility and frequency; passage of hard stools common.

• Slow transit: Prolonged transit time; infrequent bowel movements.

• Disorders of defecation: Pelvic floor or anal sphincter muscle dysfunction; associated with contraction instead of relaxation.

Secondary Causes

• Lifestyle factors: Sedentary behavior, poor fluid intake, low fiber intake.

• Medical conditions: IBS, hypothyroidism, diabetes, neurological disorders, medications (opioids, anticholinergics, calcium channel blockers).

Clinical Presentation

Signs and Symptoms	Alarm Signs/Symptoms
Infrequent bowel movements (≤ 3/week) Stool is hard, dry, small Straining during defecation Feeling of incomplete evacuation	Hematochezia Melena Anemia Unintended weight loss Nausea/vomiting

Treatment

• Lifestyle factors: Exercise, increased fluid and fiber intake (20-35g/day from vegetables, fruits, cereals).

• Medications:

  • Bulk-forming agents (fiber, methylcellulose)

  • Emollients (docusate)

  • Osmotic laxatives (lactulose, magnesium salts, sodium phosphate)

Irritable Bowel Syndrome (IBS)

Definition and Epidemiology

Irritable Bowel Syndrome (IBS) is a functional GI disorder characterized by chronic, intermittent, recurrent abdominal pain and altered bowel habits (constipation and/or diarrhea) without identifiable structural or biochemical abnormalities. It affects about 10% of the population, commonly younger patients and females.

Pathophysiology

• Central Hypothesis: Dysfunction of the brain-gut axis involving the central and enteric nervous systems, with communication via neuronal, endocrine, immune, and metabolic pathways.

• Key Factors:

  • Serotonin (5-HT) in GI tract: Regulates motility, secretion, pain perception.

  • Hypothalamic-pituitary-adrenal axis: Stress response.

  • Immune system: Inflammation, altered barrier function.

  • Microbiota: Altered gut flora.

  • Genetics: Familial predisposition.

Clinical Presentation

• Gastrointestinal symptoms: Lower abdominal pain, altered stool consistency and frequency, bloating, urgency, incomplete evacuation.

• Non-gastrointestinal symptoms: Anxiety, depression.

Diagnostic Criteria

Recurrent abdominal pain or discomfort at least 3 days per month in the last 3 months, associated with two or more of the following:

1. Relieved with defecation

2. Onset associated with a change in frequency of stool

3. Onset associated with a change in form (appearance) of stool

IBS is classified as:

• Constipation predominant (IBS-C)

• Diarrhea predominant (IBS-D)

• Mixed

• Unspecified

Treatment

• Based on IBS-C or IBS-D subtype

• General antidiarrheal or therapy for constipation as appropriate

• Serotonin receptor modulators:

  • Tegaserod (5HT-4 agonist) for IBS-C: stimulates peristalsis

  • Alosetron (5HT-3 antagonist) for IBS-D

• Secretagogues for IBS-C:

  • Lubiprostone, linaclotide, plecanatide, tenapanor: stimulate ion/water secretion into GI lumen

• Rifaximin: oral antibacterial agent for IBS-D

• Eluxadoline: opiate receptor agonist for IBS-D

Example Table: IBS Subtypes and Treatments

IBS Subtype	Main Symptoms	Treatment Options
IBS-C	Constipation	Fiber, osmotic laxatives, secretagogues, 5HT-4 agonists
IBS-D	Diarrhea	Antidiarrheals, 5HT-3 antagonists, rifaximin, eluxadoline
Mixed	Constipation & Diarrhea	Symptom-based therapy

Additional info: The pathophysiology of IBS is multifactorial, involving altered GI motility, visceral hypersensitivity, immune activation, and changes in gut microbiota. Serotonin plays a key role in regulating GI function, and its dysregulation is implicated in IBS symptoms.